Allarity Therapeutics's Q3 net loss narrows

Allarity Therapeutics

14/11/2025 14:08

Overview

Allarity receives FDA Fast Track designation for stenoparib in advanced ovarian cancer

Company reports median overall survival exceeding 25 months in Phase 2 trial

Allarity advances DRP platform through new licensing agreement

Outlook

Allarity expects to launch a Phase 2 trial for small cell lung cancer by year-end 2025

Company sees potential to broaden stenoparib’s reach in multiple cancer types

Allarity continues enrollment in Phase 2 trial for platinum-resistant ovarian cancer

Result Drivers

Research and development expenses for the third quarter of 2025 were $1.2 million, compared to $1.0 million for the third quarter of 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$2.81 mln
Q3 Operating Expenses
$2.52 mln
Q3 Operating Income
-$2.52 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Allarity Therapeutics Inc is $9.25, about 87.1% above its November 13 closing price of $1.19

Press Release: ID:nGNX1dWhzJ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)